Page 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D.C. 20549 FORM 20 - F ( Mark One ) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 ( b ) OR ( g ) OF THE SECURITIES EXCHANGE ACT OF 1934 ☑ OR ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ OR SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15 ( d ) of the Securities Exchange Act of 1934 Date of event requiring this shell company report For the transition period from Commission file number to BioLineRx Ltd. ( Exact name of Registrant as specified in its charter ) ( Translation of Registrant's name into English ) Israel ( Jurisdiction of incorporation or organization ) 2 HaMa'ayan Street Modi'in 7177871 , Israel ( Address of principal executive offices ) Philip A. Serlin +972 ( 8 ) 642-9100 +972 ( 8 ) 642-9101 ( facsimile ) phils@biolinerx.com 2 HaMa'ayan Street Modi'in 7177871 , Israel ( Name , Telephone , E - mail and / or Facsimile number and Address of Company Contact Person )